INLYTA DIN 02422891
Health Canada record
| Active ingredient(s) | AXITINIB 7 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EK01 AXITINIB |
| Original market date | |
| Current status date | 31-Mar-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AXITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02389630 | INLYTA | PFIZER CANADA ULC | Tablet | AXITINIB 1 MG | Marketed |
| 02389649 | INLYTA | PFIZER CANADA ULC | Tablet | AXITINIB 5 MG | Marketed |
| 02422883 | INLYTA | PFIZER CANADA ULC | Tablet | AXITINIB 3 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 15441 | 2014-03-24 | Supplement to a New Drug Submission (SNDS) | NEW STRENGTHS - 3.0 MG AND 7.0 MG |
International API supply for AXITINIB
7 active FDA Drug Master Files.
Request a quote for INLYTA